James Raftery on bevacizumab for metastatic colorectal cancer

Roche’s bevacizumab (Avastin) is in the news again. This has a reasonable claim to be a wonder drug, but for macular degeneration, a disease for which Roche refuses to license it. Instead Roche has tried and failed several times to have the drug recommended by NICE for lung, breast, and colorectal cancer, all at an […]

Read More…

Tracey Koehlmoos: Good Health at Low Cost: the importance of political commitment

Almost any student of global public health will be familiar with the seminal work Good Health at Low Cost.  In honor of the 25th anniversary of the release of the original book, the Rockefeller Foundation has commissioned an updated version of the book that includes five new countries or states: Ethiopia, Tamil Nadu, Kyrgyzstan, Thailand […]

Read More…